B
Bull
Bull · 25%BPMC
$182.36
Scenario price
$129.460
+0.181 (+0.14%)At close
Loading chart…
- High
- 129.550
- Open
- 129.350
- VWAP
- 129.44
- Vol
- 2.98M
- Mkt Cap
- 6.80B
- Low
- 129.300
- Amount
- 385.85M
- EV/EBITDA, TTM
- -568.81
Blueprint Medicines Corporation is a fully integrated, commercial-stage, global biopharmaceutical company. The Company invents life-changing medicines in two core, strategic areas of allergy/inflammation and oncology/hematology. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and PDGFRA Exon 18 mutant GIST in the United States and Europe. It has a pipeline of research and development programs that range from early science to advanced clinical trials in mast cell-mediated diseases, including systemic mastocytosis (SM) and chronic urticaria, breast cancer, and other solid tumors vulnerable to CDK2 inhibition. Its pipeline includes Elenestinib (BLU-263), BLU-808, and BLU-956. It is developing Elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders. It is advancing BLU-808, a potent and selective wild-type KIT inhibitor, for mast cell diseases.
Analyst Ratings (9)
+0.97% upside
Buy
9 Buy
0 Hold
0 Sell
Current: 129.46
Low
129.00
Average
130.71
High
135.00
Wells Fargo
Equal Weight
$129
2025-06-18
Wells Fargo
2025-06-18
Price Target
$129
Equal Weight
Morgan Stanley
Equal Weight
$129
2025-06-05
Morgan Stanley
2025-06-05
Price Target
$129
Equal Weight
UBS
Neutral
$129
2025-06-05
UBS
2025-06-05
Price Target
$129
Neutral
Citi
Neutral
$129
2025-06-04
Citi
2025-06-04
Price Target
$129
Neutral
Citizens JMP
Market Perform
—
2025-06-03
Citizens JMP
2025-06-03
Price Target
—
Market Perform
Valuation Metrics
The current forward P/E ratio for Blueprint Medicines Corp (BPMC) is -110.58, compared to its 5-year average forward P/E of -29.20.
Alphio AI Price Scenarios for BPMC
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Events Timeline
News
8.507-22BenzingaSanofi Expands Respiratory Vaccine Portfolio With UK Biotech Buy
3.007-20NASDAQ.COMBPMC Quantitative Stock Analysis
4.507-17NASDAQ.COMAfter Hours Most Active for Jul 16, 2025 : SRPT, NVDA, AAPL, BPMC, PFE, QQQ, INTC, CNH, GE, NI, WFC, F
8.507-14Globenewswire$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Blueprint Medicines Corporation (NASDAQ: BPMC)
9.007-08BenzingaCogent's Chronic Immune Disorder Drug Has Strong Potential To Become A Blockbuster: Analyst
BPMC FAQ — answered by Alphio AI
Blueprint Medicines Corporation is a fully integrated, commercial-stage, global biopharmaceutical company. The Company invents life-changing medicines in two core, strategic areas of allergy/inflammation and oncology/hematology. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and PDGFRA Exon 18 mutant GIST in the United States and Europe. It has a pipeline of research and development programs that range from early science to advanced clinical trials in mast cell-mediated diseases, including systemic mastocytosis (SM) and chronic urticaria, breast cancer, and other solid tumors vulnerable to CDK2 inhibition. Its pipeline includes Elenestinib (BLU-263), BLU-808, and BLU-956. It is developing Elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders. It is advancing BLU-808, a potent and selective wild-type KIT inhibitor, for mast cell diseases. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
9 analysts cover BPMC: 9 rate it Buy, 0 Hold and 0 Sell. The average price target is 130.71.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.